Cargando…

Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales

BACKGROUND: Secondary healthcare will remain pressured for some years, both because SARS-CoV-2 will circulate as a nosocomial pathogen, and owing to backlogs of patients awaiting delayed elective procedures. These stresses will drive the use of Outpatient Parenteral Antibiotic Therapy (OPAT), which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mushtaq, Shazad, Garello, Paolo, Vickers, Anna, Woodford, Neil, Livermore, David M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384802/ https://www.ncbi.nlm.nih.gov/pubmed/35972407 http://dx.doi.org/10.1093/jac/dkac280

Ejemplares similares

In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model
por: Gethers, Matthew, et al.
Publicado: (2022)

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
por: Sader, Helio S, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa
por: Mullane, Elias M, et al.
Publicado: (2019)

Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
por: Pan, Xiaolei, et al.
Publicado: (2022)

1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PSA) in a Neutropenic Murine Pneumonia Model
por: Kidd, James M, et al.
Publicado: (2019)

Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
por: Livermore, David M., et al.
Publicado: (2017)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

1598. Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime–Zidebactam (WCK-5222) Tested Against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections
por: Castanheira, Mariana, et al.
Publicado: (2019)

685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine-β-Lactamase (SBL) and Metallo-β-Lactamase (MBL) Enzymes
por: Avery, Lindsay M, et al.
Publicado: (2019)

Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
por: Thomson, Kenneth S., et al.
Publicado: (2019)

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19
por: Golden, Alyssa R., et al.
Publicado: (2022)

Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates
por: Cedano, Jose, et al.
Publicado: (2022)

Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia
por: Egge, Stephanie L., et al.
Publicado: (2023)

Distinctive Features of Ertapenem-Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort Study
por: Adelman, Max W, et al.
Publicado: (2021)

150. Low Propensity for Development of Spontaneous In Vitro Resistance to Tebipenem, Ertapenem and Meropenem Among Enterobacterales Uropathogens
por: VanScoy, Brian D, et al.
Publicado: (2022)

Efficient Synthesis of Potential Impurities in Levonadifloxacin (WCK 771)
por: Kilbile, Jaydeo T., et al.
Publicado: (2021)

Replacement of Enterococcus faecalis by Enterococcus faecium as the predominant enterococcus in UK bacteraemias
por: Horner, Carolyne, et al.
Publicado: (2021)

177. Distinctive Features of Ertapenem Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort Study
por: Adelman, Max W, et al.
Publicado: (2021)

Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
por: Dubey, Dilip, et al.
Publicado: (2023)

1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) against Enterobacterales (EB) and Pseudomonas aeruginosa (PA) in the Neutropenic Murine Thigh Infection Model
por: Gill, Christian M, et al.
Publicado: (2020)

Ertapenem Supplemented Selective Media as a New Strategy to Distinguish β-Lactam-Resistant Enterobacterales: Application to Clinical and Wastewater Samples
por: Bourles, Alexandre, et al.
Publicado: (2023)

Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales
por: Zhang, Jingjia, et al.
Publicado: (2021)

Ertapenem-Induced Thrombocytosis
por: Docobo, Ramon A, et al.
Publicado: (2017)

Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone
por: Mason, Jay W., et al.
Publicado: (2018)

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
por: Le Terrier, Christophe, et al.
Publicado: (2023)

Ertapenem Resistance of Escherichia coli
por: Lartigue, Marie-Frédérique, et al.
Publicado: (2007)

HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152
por: Yeole, R. D., et al.
Publicado: (2008)

Ertapenem rescue therapy in hidradenitis suppurativa
por: Chahine, Adam A., et al.
Publicado: (2018)

Performance of the Oxoid M.I.C.Evaluator™ Strips compared with the Etest(®) assay and BSAC agar dilution
por: Mushtaq, Shazad, et al.
Publicado: (2010)

Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014
por: Sheppard, Carmen, et al.
Publicado: (2016)

In vitro activity of lactone ketolide nafithromycin (WCK 4873) against Streptococcus pneumoniae isolates enriched with macrolide-resistance phenotype collected from mainland China
por: Zhou, Menglan, et al.
Publicado: (2022)

LINC00355:8 promotes cell proliferation and migration with invasion via the MiR-6777-3p/Wnt10b axis in Hepatocellular Carcinoma
por: Zhou, Fangyuan, et al.
Publicado: (2020)

Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution
por: Gonzalo, Ximena, et al.
Publicado: (2020)

Detection of carbapenemase-producing Enterobacterales by means of matrix-assisted laser desorption ionization time-of-flight mass spectrometry with ertapenem susceptibility-testing disks as source of carbapenem substrate
por: Shaidullina, Elvira R., et al.
Publicado: (2022)

In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
por: Mamtora, Dhruv, et al.
Publicado: (2020)

Activity of mecillinam against carbapenem-resistant Enterobacterales
por: Emeraud, Cécile, et al.
Publicado: (2022)

Ertapenem for treatment of osteomyelitis: a case series
por: Goswami, Neela D, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_o1hr03a1rgbqqvhhheg9jm2281